Literature DB >> 30102892

Distinctive temporal profiles of detergent-soluble and -insoluble tau and Aβ species in human Alzheimer's disease.

David J Koss1, Marina Dubini2, Heather Buchanan2, Claire Hull2, Bettina Platt3.   

Abstract

Alzheimer's disease (AD) pathology relevant proteins tau and beta-amyloid (Aβ) exist as an array of post-translationally modified and conformationally altered species with varying abundance, solubility and toxicity. Insoluble neurofibrillary tau tangles and Aβ plaques are end-stage AD hallmarks, yet may carry less disease significance compared to soluble species. At present, it is unclear how soluble and insoluble tau and Aβ relate to each other as well as to disease progression. Here, detergent soluble and insoluble fractions generated from post-mortem human temporal lobe samples (Brodmann area 21) were probed for tau and Aβ markers in immuno-dot assays. Measures were quantified according to diagnosis (AD cf. Non-AD), neuropathological severity, and correlated with disease progression (Braak stages). All markers were elevated within AD cases cf. non-AD controls (p < 0.05) independent of solubility. However, when considered according to neuropathological severity, phospho-tau (detected via CP13 and AT8 antibodies) was elevated early within the soluble fraction (p < 0.05 intermediate cf. low severity) and emerged only later within the insoluble fraction (p < 0.05 high cf. low severity). In contrast, PHF1 phospho-tau, TOC1 reactive tau oligomers and amyloid markers rose within the two fractions simultaneously. Independent of solubility, cognitive correlations were observed for tau makers and for fibrillary amyloid (OC), however only soluble total Aβ was significantly correlated with intellectual impairment. Following the exclusion of end-stage cases, only soluble total Aβ remained correlated with cognition. The data indicate differential rates of protein aggregation during AD progression and confirm the disease relevance of early emerging soluble Aβ species. Crown
Copyright © 2018. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Aggregation; Alzheimer’s disease; Pathology; Tau; β-amyloid

Mesh:

Substances:

Year:  2018        PMID: 30102892     DOI: 10.1016/j.brainres.2018.08.014

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  4 in total

Review 1.  Therapeutic Targeting of Rab GTPases: Relevance for Alzheimer's Disease.

Authors:  Kate L Jordan; David J Koss; Tiago F Outeiro; Flaviano Giorgini
Journal:  Biomedicines       Date:  2022-05-16

2.  Hyperphosphorylated Human Tau Accumulates at the Synapse, Localizing on Synaptic Mitochondrial Outer Membranes and Disrupting Respiration in a Mouse Model of Tauopathy.

Authors:  Andrew J Trease; Joseph W George; Nashanthea J Roland; Eliezer Z Lichter; Katy Emanuel; Steven Totusek; Howard S Fox; Kelly L Stauch
Journal:  Front Mol Neurosci       Date:  2022-03-10       Impact factor: 5.639

3.  RT-QuIC Using C-Terminally Truncated α-Synuclein Forms Detects Differences in Seeding Propensity of Different Brain Regions from Synucleinopathies.

Authors:  Ilaria Poggiolini; Daniel Erskine; Nishant N Vaikath; Janarthanan Ponraj; Said Mansour; Christopher M Morris; Omar M A El-Agnaf
Journal:  Biomolecules       Date:  2021-05-31

4.  Synaptic Loss, ER Stress and Neuro-Inflammation Emerge Late in the Lateral Temporal Cortex and Associate with Progressive Tau Pathology in Alzheimer's Disease.

Authors:  Heather Buchanan; Murray Mackay; Kerri Palmer; Karolína Tothová; Miroslava Katsur; Bettina Platt; David J Koss
Journal:  Mol Neurobiol       Date:  2020-06-08       Impact factor: 5.682

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.